{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-000900","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.721710+00:00","generated_at":"2026-06-20T18:08:43.186880+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Anebulo: Phase 2 data show ANEB-001 reduces THC effects; cash $16M runway into 2024","bullets":["Preliminary data: single 10 mg ANEB-001 reversed key psychotropic effects of 30 mg THC, including feeling high and body sway.","Delayed dosing of ANEB-001 (1 hour after THC) rapidly reversed pre-existing effects.","Full PK, PD, and safety data expected by end of 1Q2023; FDA End of Phase 2A meeting targeted H1 2023.","Cash of $16M as of Dec 31, 2022 provides runway into 2024.","No serious adverse events; 134 subjects enrolled in Parts A and B."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-000900","json":"https://secwatch.observer/filing/0001493152-23-000900.json","markdown":"https://secwatch.observer/filing/0001493152-23-000900.md","text":"https://secwatch.observer/filing/0001493152-23-000900.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223000900/0001493152-23-000900-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223000900/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:08:43.186880+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}